United States · Series C startup
4 rounds we have observed, with the 6 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$31Mraised across 4 rounds since 2009, from 4 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
OrbiMed
F-Prime CapitalReported by FinSMEs
Golden Angels InvestorsFrom a historical funding recordSEC filing: $820K sold, first sale Dec 2013
Reported by sec.govSEC filing: $750K sold, first sale Mar 2013
From a historical funding recordSEC filing: $1.7M sold, first sale Aug 2009
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Golden Angels InvestorsOrbiMedF-Prime CapitalAisling Capital/ Black PearlBlack Horse InvestmentsGolden Angel Network et alMissing a round, or an investor who was in one? Tell us.
Promentis Pharmaceuticals's investors include Golden Angels Investors, OrbiMed, F-Prime Capital, Aisling Capital/ Black Pearl and Black Horse Investments, and 1 more on record.
Promentis Pharmaceuticals has raised $31M across 4 rounds since 2009.
Promentis Pharmaceuticals's most recent round was a Series C of $26M in Mar 2017.
Its most recent round, $26M in Mar 2017, is also its largest on record.
Promentis Pharmaceuticals's first round on record, in Aug 2009, was backed by Golden Angels Investors.
Promentis Pharmaceuticals's latest named round is a Series C, in Mar 2017.
Promentis Pharmaceuticals is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
